Alphamab Oncology (HKG:9966)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.90
-0.08 (-0.89%)
May 23, 2025, 4:08 PM HKT
81.63%
Market Cap 8.64B
Revenue (ttm) 681.16M
Net Income (ttm) 177.02M
Shares Out 961.97M
EPS (ttm) 0.18
PE Ratio 49.64
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,889,000
Average Volume 3,670,363
Open 9.16
Previous Close 8.98
Day's Range 8.81 - 9.35
52-Week Range 2.00 - 9.35
Beta 0.41
RSI 67.36
Earnings Date May 15, 2025

About Alphamab Oncology

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology biologics. The company commercializes KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENQEIDA brand name. Its product pipeline includes KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antiboday that is i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 420
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9966
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.